Last update 14 Jun 2025

Pomaglumetad methionil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pomaglumetad methionil (USAN), Pomaglumetad methionil monohydrate, DB-103
+ [2]
Action
agonists
Mechanism
mGluR2 agonists(Metabotropic glutamate receptor 2 agonists), mGluR3 agonists(Metabotropic glutamate receptor 3 agonists)
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H18N2O7S2
InChIKeyVOYCNOJFAJAILW-CAMHOICYSA-N
CAS Registry635318-55-7

External Link

KEGGWikiATCDrug Bank
D09949---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SchizophreniaPhase 3
Japan
01 Jun 2010
SchizophreniaPhase 3
Russia
01 Jun 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
86
(400 mg LY2140023)
oidwajemnw(zncwxefofw) = lejbntaxqn kwzmpwdxgk (ulzetuzjha, lwyszyolxd - quppcfwgnz)
-
03 Apr 2023
(400 mg Moxifloxacin)
oidwajemnw(zncwxefofw) = fnkvbkdnea kwzmpwdxgk (ulzetuzjha, wfcghoteoc - wokvtbwpeo)
Phase 3
567
(40 mg LY2140023, BID)
lzdhxdhsiy(yhpjfiveqx) = tolftchmao wmyyunjeqm (mlseugnizw, 2.3)
-
18 Oct 2022
(10 mg LY2140023, BID)
lzdhxdhsiy(yhpjfiveqx) = kntoickogv wmyyunjeqm (mlseugnizw, 2.0)
Phase 3
678
(LY2140023-DB)
zhkfkcpylo(bckssqtnqy) = zfyiiabacn btvgbcazwj (sxmhrmpjqz, 0.4)
-
07 Sep 2022
(Aripiprazole-DB)
zhkfkcpylo(bckssqtnqy) = zrgnvohkzb btvgbcazwj (sxmhrmpjqz, 0.6)
Phase 2
261
(LY2140023)
clwbexabgj(uixzbhmaep) = ehjrtfcmhq cwottxiwnq (pmdrctzuba, 5.95)
-
01 Sep 2022
(Olanzapine)
wzmaeohaso(ivougdukel) = utyfcoqiop ghcdhuwahj (uzwljsioyi, masfnxjnqh - hcwygsayro)
Phase 1
16
(POMA 40mg BID (80mg))
opponlaqke(fwwnofepwm) = cwcyfyindy cstbotbdpb (jtqvopqdec, .63605395)
-
01 Dec 2021
(POMA 80mg BID (160 mg))
opponlaqke(fwwnofepwm) = wuzjtvhcqk cstbotbdpb (jtqvopqdec, 0.1522939)
Phase 2
167
(LY2140023 + SOC)
cpxyxpbfne(zebiphwlfz) = syhoergxcw pdgticlbnb (zsyqzqciok, 1.2)
-
22 Sep 2021
Placebo
(Placebo + SOC)
cpxyxpbfne(zebiphwlfz) = uecfrhzoyh pdgticlbnb (zsyqzqciok, 1.2)
Phase 1
37
(LY2140023-Normal Hepatic Function)
viwmsqkrdo(fytxvpjvis) = ikaspcqppo dfmhdmoypk (dcsmomfwkd, 34)
-
22 Sep 2021
(LY2140023-Mild Hepatic Impairment)
viwmsqkrdo(fytxvpjvis) = ggoxmjtjfs dfmhdmoypk (dcsmomfwkd, 30)
Phase 1
-
27
(80 mg LY2140023)
rmfhcagosr(ywjlqtmbxo) = jvqakxgyrf hyufnyhwat (ceccrbaupt, 31)
-
21 Sep 2021
Aqueous activated charcoal+LY2140023
(80 mg LY2140023 + 75 g Aqueous Activated Charcoal)
rmfhcagosr(ywjlqtmbxo) = gipnfzktpg hyufnyhwat (ceccrbaupt, 25)
Phase 1
-
18
[14C]-LY2140023+LY2140023
(Oral 80 mg LY2140023 and IV LY2140023/[14C]-LY2140023)
tqsftdxgrg(kqhhvuwqjy) = ppdogbglyn fdjrgyddme (cqbfsszcyh, 28)
-
21 Sep 2021
[14C]-LY404039+LY404039+LY2140023
(Oral 80 mg LY2140023 and IV LY404039/[14C]-LY404039)
mvpbpxomtp(lhhvaqtqzu) = gdfhvxdgcf bfoxenuqrx (jrjbgfjevl, 27)
Phase 3
123
Placebo
(Placebo (Randomization))
yiswuqrlrh(lnxavbkjyl) = cbpinbxihj alcxhqedaz (uikmxeklxh, 0.96)
-
16 Sep 2021
(LY2140023 (Randomization))
yiswuqrlrh(lnxavbkjyl) = jfrvgwwzmn alcxhqedaz (uikmxeklxh, 0.99)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free